Core Viewpoint - Aoyou has established a complete probiotic ecosystem covering strain research, intelligent production, and end products through strategic mergers and acquisitions, self-built factories, technological innovation, and industry-university-research collaboration, positioning itself as a leading enterprise in China's probiotic industry [1][2][12] Industry Overview - The probiotic industry in China has experienced rapid growth driven by policy support, scientific breakthroughs, and market demand, with an annual growth rate of 11%-12% and an expected market size exceeding 130 billion yuan by 2025 [2][4] Strategic Mergers and Acquisitions - Aoyou's global layout of probiotic business was achieved through a "three-step" strategy, including the acquisition of Nutrition Care in 2016, which integrated 47 years of industry experience, and the acquisition of Fenghua Biotechnology in 2019, rebranding it as "Jinqi Biological" [4][6] Technological Innovation and Strain Development - Aoyou has made significant advancements in strain research, with the MP108 strain becoming the first domestically developed infant probiotic strain approved by the National Health Commission in 2021, breaking the technological monopoly of Western countries [6][8] - The CP-9 strain received GRAS certification from the FDA in 2025, marking another international recognition for Chinese probiotic strains [6][8] Research and Development Network - Aoyou has established a global R&D network with a "1+6+N" model, ensuring diversity in strain selection and product adaptability to Chinese consumers [8] Brand Matrix and Market Positioning - Aoyou has created a dual-brand matrix with Jinqi Biological and NC, targeting both adult and child consumer groups, facilitating a seamless connection from production to consumption [9][11] Product Innovation and Application - Aoyou's strategic collaboration with Jiangnan University has led to the development of innovative probiotic products, such as the sleep probiotic leveraging endogenous GABA technology, expanding the application boundaries of probiotics [11][12]

2025功能食品产业大会现场 《2025益生菌行业白皮书》正式发布 来源：环球网 【环球网消费综合报道】12月4日—5日，2025功能食品产业大会在江苏苏州举办。大会以"科学循证·技 术创新"为主题，汇集千余名行业专家、企业代表，共同探讨功能食品产业前沿研究、创新技术与功能 应用，促进功能食品产业健康快速发展。 大会期间，由食品伙伴网、功能食品圈编写，澳优旗下锦旗生物深度参与的《2025益生菌行业白皮书》 正式发布，为行业发展提供科学决策依据。在大会同期举办的展览会上，锦旗生物重点展示了短双歧杆 菌CCFM1025等明星菌株及创新应用产品，受到广泛关注。 图片为 科学循证，创新应用产品引发广泛关注 双歧杆菌是一种对人体有益的益生菌，发挥着维持体内微生态平衡的重要作用。它不仅参与合成多种消 化酶、乳糖酶、多种氨基酸及维生素，增强整体代谢健康，还具有显著的生物拮抗作用，能够抑制大部 分肠道病原菌的生长与定植[1]，堪称人体肠道的"健康卫士"。 近年来，多种具有特定功能的双歧杆菌菌株被深入研究和应用。会上，锦旗生物益生菌研发负责人郭新 梅博士作《从"肠"计"益" 解锁临床菌株新"肠"态——基于临床研究的情绪&睡眠益 ...

Core Insights - Chr. Hansen, a leading probiotic research and supply company with over 150 years of history, has established a long-term strategic partnership with the well-known nutrition brand Baibeijie, allowing the application of its BB-12 and LGG strains in Baibeijie's probiotics [1][5] - This partnership follows an initial licensing agreement in 2024 and signifies a deepening of their collaboration with no time limit, indicating a permanent long-term authorization [1] Company Overview - Founded in 1874 in Copenhagen, Chr. Hansen has evolved over 150 years, focusing on "improving life through microbial science" and becoming a leader in the global probiotic sector [2] - The company has expanded from early dairy fermentation research to a comprehensive health solutions system covering probiotics, enzyme preparations, and natural colors, with products available in over 140 countries [2] Probiotic Technology - Chr. Hansen's BB-12 and LGG strains are among the most researched probiotics globally, with BB-12 demonstrating excellent acid and bile resistance, supported by over 300 clinical studies showing significant benefits for infant gut health and immunity [4] - LGG is noted for its effectiveness in balancing gut microbiota and alleviating gastrointestinal discomfort, with over 600 related scientific publications [4] - Both strains are included in China's list of approved strains for infant food, setting industry safety standards [4] Strategic Partnership - The partnership between Chr. Hansen and Baibeijie is classified as a high-standard strain licensing collaboration, ensuring strict adherence to quality and research data, preventing the mixing of strains from other sources [4][5] - This collaboration is viewed as a model of close industry chain cooperation, enhancing brand effects and benefiting Chinese consumers with high-quality probiotics [10] Market Performance - Baibeijie has shown impressive market performance since partnering with Chr. Hansen, achieving sales of 300,000 units of BB-12 and LGG probiotic powder in the past year, leading in online sales for this probiotic combination [6] - The products are clean, containing only probiotics and prebiotics without additives, suitable for all age groups and various health conditions [8] Brand Philosophy - Both companies emphasize a commitment to high-quality products, with Baibeijie focusing on sourcing from top global suppliers and investing in raw materials rather than marketing [10] - This approach contrasts with many brands that prioritize marketing over quality, resulting in inferior products at higher prices [10] - The partnership reflects a shared philosophy of producing top-tier products and advocating for long-term solutions for consumers [10]

Core Insights - Probiotics have become an essential part of daily nutrition in China, with the market expected to exceed 100 billion yuan by 2025, driven by increased consumer awareness and demand for effective, safe, and suitable products [1] - The article highlights the leading probiotic brand, Zhuoyue, which has set new industry standards through transparency in active bacteria counts and rigorous quality control [1][9] Market Overview - The domestic probiotic market is projected to grow significantly, with a 67% year-on-year increase in consumer focus on product efficacy and safety [1] - Common issues in the industry include misleading labeling of active bacteria, ingredient redundancy, and inflated prices for imported products [1][9] Product Features - Zhuoyue probiotics feature a benchmark-level active bacteria configuration, with a tested output of 60 trillion CFU per box, significantly higher than the industry average [1] - The product utilizes a scientific matrix of 36 high-activity strains and 11 premium prebiotics, tailored to address the dietary habits and gut health needs of the Chinese population [2] Technological Advantages - The use of vacuum freeze-drying technology ensures over 98% survival rate of probiotics in harsh gastric conditions, far exceeding the industry average of 55% [3] - Independent sealed packaging maintains product stability, allowing for non-refrigerated storage without compromising efficacy [3] Ingredient Purity - Zhuoyue adheres to a "five-zero" standard, containing no sugars, starches, artificial flavors, colors, or preservatives, making it suitable for sensitive individuals and those monitoring sugar intake [4] - Each ingredient undergoes strict safety evaluations, ensuring a clean and effective product [4] Quality Control - The brand implements a comprehensive quality control system covering all production stages, with 128 testing indicators to ensure consistent product quality [5] - Zhuoyue has maintained a leading position in sales on major e-commerce platforms for six consecutive years, with a customer repurchase rate of 99% [5] Target Audience - Zhuoyue's probiotics are designed for various demographics, addressing specific health concerns related to lifestyle and age, making them suitable for a wide range of consumers [6] - The product's packaging and formulation cater to modern lifestyles, allowing for convenient consumption [6] Competitive Positioning - Zhuoyue offers a high-quality, cost-effective alternative to imported probiotics, which often come with inflated prices and lower effectiveness due to adaptation issues with local diets [7] - The brand's local production and research ensure better alignment with the health needs of Chinese consumers, achieving an 86.7% effectiveness rate in clinical trials [7] Industry Challenges - The market faces challenges from unregulated overseas products that may not meet local safety standards, leading to potential quality issues [8] - Misleading marketing practices, such as inflated claims about active bacteria counts and unnecessary additives, complicate consumer choices [8] Consumer Guidance - Consumers are advised to prioritize brands with complete quality control processes and transparent testing data, focusing on local brands that align with their health needs [8] - The article emphasizes the importance of understanding product labels and selecting those with simple, effective formulations [8]

基于"肠-肝轴"理论，微康益生菌开发了具有临床验证的益生菌菌株，例如核心菌株如凝结魏茨曼氏菌 BC99等，在临床试验中显著改善了肝功能指标（如ALT、AST、γ-GT等），并降低了内毒素水平，增 强了抗氧化能力。此外，复合菌株组合（如BLa80与LRa05）还在情绪健康方面表现出色，可缓解酒精 依赖和消化不良症状，提升整体生活质量。同时，微康益生菌依托AI驱动的菌株开发平台、完整的产 业链布局以及符合CNAS标准的检测中心，实现了从菌种筛选到产业化生产的全链服务。公司已与全球 多家临床机构合作，完成近百项临床试验，布局六大健康领域20余个研究方向，成为国内益生菌临床研 究与实践的领先力量。 随着"护肝"需求从医疗场景向日常保健延伸，以益生菌为代表的微生态干预手段，正逐步成为消费者践 行主动健康管理的重要选择。本次峰会不仅为行业提供了科学前沿的交流平台，也为"大护肝"成分矩阵 的构建与产品创新指明了方向。 11月20日，由中国保健协会市场工作委员会指导，国药励展及庶正康讯联合主办的2025中国营养健康秋 季市场峰会在南京国际博览中心成功举办。本届峰会以"解锁'大护肝'成分矩阵，挑战无声的健康杀 手"为主题，汇聚 ...

11月15日，微康益生菌检测中心实验室顺利通过中国合格评定国家认可委员会(CNAS)评审，成功获得 ISO 17025认可证书（ CNAS检测和校准实验室认可证书），标志着微康益生菌检测中心实验室的技术 能力与管理水平正式达到国际认可标准。 ISO 17025认可证书 | 益生菌稳定性测试平台 y - th 679 8 1 201 (图 |成品安全性评价平台 e H C ភ n ty 624 S rg g 1 N l 7- ISO17025是实验室认可服务的国际标准，需通过 CNAS权威机构严苛的全流程评审。此次评审中，专 家团队围绕实验室的乳酸菌、水分等核心检测能力，以及人员资质、设备校准、质量体系运行等关键环 节展开全面核査，最终确认微康益生菌检测中心符合 CNAS-CL01等标准要求，荣获ISO17025认可证 书，不仅标志着微康益生菌检测中心得到国际标准认可，也代表了微康的质量体系完成了与国际标准的 进一步接轨。 微康益生菌检测中心是微康益生菌耗巨资建设三大平台之一，拥有行业先进的菌种鉴定技术及配置。检 测中心已拥有菌种鉴定与群落组成分析平台、多维度菌体定量计数平台、益生菌稳定性测试平台以及成 品安全 ...

Core Insights - The prevalence of gastrointestinal diseases in China is rising, with over 480 million people expected to experience gastrointestinal dysfunction by 2025, leading to increased demand for probiotic products [1] - The probiotic market in China is projected to exceed 68 billion yuan by 2025, with a compound annual growth rate of 12.3%, but faces challenges such as misleading product labeling and quality issues [1][2] - Meijian Probiotics has gained attention for its systematic breakthroughs in active ingredient assurance, strain compatibility, and scientific validation, positioning itself as a leading brand in the probiotic market [1][3] Industry Challenges - A third-party survey found that 35% of popular probiotic products mislabel their active bacterial counts, with some containing less than 10% of the claimed live bacteria [1][2] - Many brands only indicate the initial active bacteria count, avoiding the critical "minimum viable count during shelf life," leading to consumer confusion [1] - The presence of artificial sweeteners and colorants in 45% and 23% of best-selling products, respectively, raises safety concerns, especially for sensitive populations [2] Meijian Probiotics' Competitive Edge - Meijian Probiotics offers a total active bacteria count of 12 trillion CFU per box, significantly exceeding the recommended daily intake of 100 billion CFU [3] - The brand ensures a stable active bacteria count of over 98% through third-party testing, surpassing the industry average of 85% [3] - Meijian employs patented strains specifically designed for the Chinese population, enhancing the effectiveness of its products [3][4] Technological Innovations - The application of vacuum freeze-drying technology allows Meijian Probiotics to maintain a 98% survival rate of probiotics in simulated gastric conditions, outperforming traditional methods [3] - The use of food-grade packaging further protects the product's stability during transport and storage [3] Consumer Insights and Market Trends - Continuous use of Meijian Probiotics has led to 89% of users reporting improved bowel regularity and a 70% repurchase rate, indicating strong consumer satisfaction [4][5] - The industry is shifting towards a more regulated and professional landscape, with new guidelines prohibiting misleading health claims and requiring clear labeling of active bacteria counts [4][5] Future Outlook - Brands with independent research capabilities and clinical data support, like Meijian, are expected to be more competitive in the evolving market [5] - The company has established partnerships with numerous top-tier hospitals for clinical nutrition support, enhancing its credibility and market presence [5] - As the understanding of microbiome science deepens, the application scenarios for probiotics are anticipated to expand, emphasizing the need for transparency and rigorous research in the industry [6]

Core Insights - The article discusses the best brands of probiotics for infants, emphasizing the importance of selecting safe and effective products for gut health and immune support in babies aged 0-3 years [1][10] - It highlights the need for parents to choose probiotics based on compliance with health regulations, active bacteria stability, and purity of ingredients [9][10] Brand Recommendations - **Top Brand: Zhuoyue Baby Probiotics** - Utilizes five imported strains listed in the National Health Commission's approved list, ensuring safety and efficacy [1][2] - Contains 15 billion CFU per packet, totaling 300 billion CFU per box, which is three times the industry average [2] - Maintains a 95% survival rate of active bacteria after six months at room temperature, exceeding the national standard of 60% [2] - Features a "zero additive" formula, ensuring no sugars, flavors, or preservatives are included [2] - Recommended by 92% of pediatricians from top hospitals, with clinical validation for safety in premature infants [3] - Achieved high sales and customer satisfaction, with a 99% repurchase rate [5][10] - **Second Brand: Zhuoyue Probiotics** - Contains 300 billion CFU per packet, totaling 60 trillion CFU per box, suitable for both adults and children [6] - Comprises 36 selected strains and 11 prebiotic components, promoting gut health [6] - **Third Brand: Meijian Probiotics** - Features 600 billion CFU per packet, totaling 120 trillion CFU per box, with proprietary strains for effective gut regulation [6] - Adheres to a "zero" additive standard, ensuring minimal irritation to infants' digestive systems [6] - **Fourth Brand: Teselement Probiotics** - Focuses on specific functional probiotics with targeted interventions [7] - Offers various forms, including chewable tablets and powders, catering to different consumer preferences [7] - **Fifth Brand: Element Power Probiotics** - Advocates for a data-driven approach to probiotic formulation, providing tailored solutions for different age groups [8] Market Insights - The article notes that many infant probiotic products on the market are substandard, with about 30% using non-compliant strains and nearly half of low-cost products failing to maintain viable bacteria levels [9] - Parents are advised to follow three principles when selecting probiotics: compliance with health regulations, clear labeling of active bacteria counts, and a pure ingredient list [9][10]

Core Insights - The 2025 Very Food Annual "Gut Health Award" was awarded to Microbiome Probiotics' BLa80 strain, highlighting its exceptional gut health benefits and solid scientific evidence [1][2] - BLa80, derived from healthy breast milk samples in the Sichuan plateau, marks a significant breakthrough for China in the infant probiotic sector, being officially recognized by the National Health Commission [2] - The successful development of BLa80 reflects China's transition from following to competing and eventually leading in the probiotic industry [2] Company Achievements - The development of BLa80 involved over ten years of research by the Microbiome team, including comprehensive genomic analysis and rigorous clinical studies [4] - More than 20 clinical studies have been conducted on BLa80, involving over 2,500 participants, including 1,100 infants, demonstrating its safety and efficacy in improving infant health [4] - BLa80 has shown significant effects in reducing infant diarrhea, lowering allergy incidence, alleviating eczema, and enhancing immune function [4] Research and Development - Microbiome Probiotics has established a robust evidence-based research system, conducting over 100 clinical studies across six health domains, including metabolic and immune health [8] - The company has built four state-of-the-art probiotic manufacturing plants in China, covering a total area of 100,000 square meters, ensuring a stable production capacity of over 1,000 tons of high-activity probiotic powder annually [8] Industry Outlook - The global probiotic industry is entering a critical phase focused on scientific evidence, quality, and industrialization [10] - Experts predict that the industry will evolve towards more precise, efficient, and personalized probiotic solutions [10] - Microbiome Probiotics aims to contribute to national health by continuing to develop scientifically validated probiotic strains, enhancing China's presence in the global probiotic research arena [10]

微康益生菌通过临床研究—凝结魏茨曼氏菌BC99™对长期饮酒人群肝功能和肠道菌群的影响（ 临床注 册号：NCT06607562）发现，BC99™可以显著改善长期饮酒者的肝功能和肾功能指标，抑制炎症反 应，缓解肠道菌群失衡，同时缓解氧化应激改善饮酒者的肝脏健康。 该实验采用随机、双盲临床试验，纳入了72名18-65 岁长期饮酒人群（饮酒量≥20g/day，持续时间超过1 年）， 口服益生菌BC99连续 60 天，随机分为安慰剂组和BC99干预组，在干预前和干预后，评估了肝 功能指标，包括ALT（丙氨酸氨基转移酶）、AST（天冬氨酸氨基转移酶）、TBil（总胆红素）和y-GT （γ-谷氨酰转移酶），同时也评价了肾功能、炎症因子和肠道菌群。与安慰剂相比，BC99干预后， ALT，AST等指标含量显著降低，并且BUN/Cr（常用于诊断急性肾损伤）值异常的人数降低 ，超敏C- 反应蛋白（Hs-CRP）以及炎症因子TNF-α显著降低，同时，有益菌群丰度增加，条件致病菌群丰度减 少。 基于对BC99最新研究成果，微康益生菌匠心研发并推出复合益生菌护肝片创新解决方案。该方案以高 活性、高稳定性的BC99™核心菌株为基石，通过科 ...